What does Biolinq do?
Biolinq is a healthcare technology company that designs and develops precision multi-analyte biosensors. Their innovative wearable sensor patch, which features a color-changing indicator for real-time glucose monitoring, is aimed at enhancing metabolic health and enabling future multi-analyte sensing capabilities.
How much did they raise?
The company raised $100M in Series C financing. The round was led by Alpha Wave Ventures, with participation from RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical, and Features Capital.
What are their plans for the money?
Biolinq plans to use the funds to transition from the development stage to commercial readiness, with a focus on completing a US pivotal trial and progressing toward regulatory submission. This move is expected to accelerate the commercialization of its advanced wearable biosensor technology.
What have they achieved so far?
The company has already demonstrated the potential of its technology with the success of its glucose sensor patch, which provides real-time feedback and is designed for ease of use, paving the way for further advancements in metabolic health monitoring.
